Celea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.
Jul 5, 2026TwelveLabs' $100M video-AI raise and Celea Therapeutics' $180M biotech round show growth-stage investors writing nine-figure checks into narrow, vertical AI applications again, not just horizontal infrastructure plays.
Jul 4, 2026Celea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.
Jul 2, 2026PureTech-founded Celea Therapeutics raised $180 million to fund a head-to-head Phase 3 trial testing its drug deupirfenidone against the current standard of care for idiopathic pulmonary fibrosis.
Jul 2, 2026